Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cerebral vs. Cardiovascular Responses to Exercise in Type 2 Diabetic Patients

    Research output: Contribution to journalReviewResearchpeer-review

  3. Macrophage Subpopulations and the Acute Inflammatory Response of Elderly Human Skeletal Muscle to Physiological Resistance Exercise

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study

    Research output: Contribution to journalReviewResearchpeer-review

  3. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms

    Research output: Contribution to journalReviewResearchpeer-review

  • Nikolaj Worm Ørntoft
  • Michel Blé
  • Anna Baiges
  • Jose Ferrusquia
  • Virginia Hernández-Gea
  • Fanny Turon
  • Marta Magaz
  • Søren Møller
  • Holger Jon Møller
  • Juan Carlos Garcia-Pagan
  • Henning Gronbaek
View graph of relations

Introduction: Macrophages are involved in development and progression of chronic liver disease and portal hypertension. The macrophage activation markers soluble (s)CD163 and soluble mannose receptor (sMR), are associated with portal hypertension in patient with liver cirrhosis but never investigated in patients with non-cirrhotic portal hypertension. We hypothesized higher levels in cirrhotic patients with portal hypertension than patients with non-cirrhotic portal hypertension. We investigated sCD163 and sMR levels in patients with portal hypertension due to idiopathic portal hypertension (IPH) and portal vein thrombosis (PVT) in patients with and without cirrhosis.

Methods: We studied plasma sCD163 and sMR levels in patients with IPH (n = 26), non-cirrhotic PVT (n = 20), patients with cirrhosis without PVT (n = 31) and with PVT (n = 17), and healthy controls (n = 15).

Results: Median sCD163 concentration was 1.51 (95% CI: 1.24-1.83) mg/L in healthy controls, 1.96 (95% CI: 1.49-2.56) in patients with non-cirrhotic PVT and 2.16 (95% CI: 1.75-2.66) in patients with IPH. There was no difference between non-cirrhotic PVT patients and healthy controls, whereas IPH patients had significantly higher levels than controls (P < 0.05). The median sCD163 was significantly higher in the cirrhotic groups compared to the other groups, with a median sCD163 of 6.31 (95% CI: 5.16-7.73) in cirrhotics without PVT and 5.19 (95% CI: 4.18-6.46) with PVT (P < 0.01, all). Similar differences were observed for sMR.

Conclusion: Soluble CD163 and sMR levels are elevated in patients with IPH and patients with cirrhosis, but normal in patients with non-cirrhotic PVT. This suggests that hepatic macrophage activation is more driven by the underlying liver disease with cirrhosis than portal hypertension.

Original languageEnglish
Article number649668
JournalFrontiers in Physiology
Volume12
ISSN1664-042X
DOIs
Publication statusPublished - 11 Jun 2021

    Research areas

  • portal hypertension, cirrhosis, macrophages, non-cirrhotic portal hypertension, biomarker

ID: 66508541